BiotechTube

EscharEx 5% (EX-02 formulation)

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Superficial Basal Cell Carcinoma

Conditions

Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma

Trial Timeline

Jun 30, 2021 → Jun 1, 2022

NCT ID
NCT05157763

About EscharEx 5% (EX-02 formulation)

EscharEx 5% (EX-02 formulation) is a phase 1/2 stage product being developed by MediWound for Superficial Basal Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05157763. Target conditions include Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma.

What happened to similar drugs?

2 of 5 similar drugs in Superficial Basal Cell Carcinoma were approved

Approved (2) Terminated (1) Active (2)
✅Diclofenac gelNovartisApproved
✅Dalteparin sodium injectionPfizerApproved
🔄Rivaroxaban + FondaparinuxBayerPhase 3
🔄Rivaroxaban + PlaceboBayerPhase 3
❌NDV-01 (sustained-release gemcitabine-docetaxel)Relmada TherapeuticsPhase 3

Hype Score Breakdown

Clinical
9
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05157763Phase 1/2Recruiting

Competing Products

11 competing products in Superficial Basal Cell Carcinoma

See all competitors
ProductCompanyStageHype Score
EG-70 (phase 1) + EG-70 (phase 2)enGenePhase 1/2
29
GemcitabineEli LillyPhase 2
35
Gemcitabine + mitomycin CEli LillyPhase 2
35
MK-3475 and BCGMerckPhase 2
42
Diclofenac gelNovartisApproved
43
LDE225 0.75% + VehicleNovartisPhase 2
27
Dalteparin sodium injectionPfizerApproved
43
Rivaroxaban + FondaparinuxBayerPhase 3
37
Rivaroxaban + PlaceboBayerPhase 3
37
ChemophaseHalozyme TherapeuticsPhase 1
26
NDV-01 (sustained-release gemcitabine-docetaxel)Relmada TherapeuticsPhase 3
26